Pliant Therapeutics Inc (STU:9PT)
€ 12.5 -0.7 (-5.3%) Market Cap: 778.32 Mil Enterprise Value: 448.21 Mil PE Ratio: 0 PB Ratio: 2.37 GF Score: 36/100

Pliant Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript

May 17, 2023 / 05:35PM GMT
Release Date Price: €20 (-0.99%)
Brian Abrahams
RBC Capital Markets - Analyst

I'm Brian Abrahams, one of the senior biotech analysts at RBC Capital Markets. Our next presenting company is Pliant Therapeutics. I'm very pleased to have their CFO, Keith Cummings; and their Chief Medical Officer, Ãric Lefebvre. So Keith and Eric, thanks again.

Ã;ric Lefebvre
Pliant Therapeutics, Inc. - Chief Medical Officer

Thank you.

Keith Cummings
Pliant Therapeutics, Inc. - CFO

Thank you.

Questions & Answers

Brian Abrahams
RBC Capital Markets - Analyst

So maybe just kicking things off, you guys recently presented some updated data for bexo and your Phase 2 IPF study. Can you maybe just run us through the key highlights from that data, maybe the Phase 2 overall and then the six-month data at the 320-mg dose that I think has been the most recent data you have talked about.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot